Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Raises Price Target to $33
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Maneka Mirchandaney maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $26 to $33.
Evercore ISI Group analyst Maneka Mirchandaney maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $26 to $33.